Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bruin Pharmaceuticals
The big pharma company and its new partner both expect demand to continue for pre-exposure prophylaxis antibody therapies, for COVID-19 and beyond.
AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.
Plus deals involving Neumora/Vanderbilt, Active Biotech/Oncode, and Bridge/Scripps.
Private Company Edition: Panelists at Biocom’s Global Life Science Partnering Conference noted a shift in the types of early-stage drug developers getting venture funding going forward. In recent financings, Synthego closed a $200m series E and Plexium raised $102m.